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Abstract
Background: Ameloblastomas are odontogenic neoplasms characterized by local invasiveness.
This study was conducted to address the role of matrix metalloproteinase-2 (MMP-2) in the
invasiveness of ameloblastomas.
Methods: Plasmids containing either MMP-2 siRNA or tissue inhibitor of metalloproteinase-2
(TIMP-2) cDNA were created and subsequently transfected into primary ameloblastoma cells.
Zymography, RT-PCR, and Western blots were used to assess MMP-2 activity and expression of
MMP-2 and TIMP-2, as well as protein levels.
Results: Primary cultures of ameloblastoma cells expressed cytokeratin (CK) 14 and 16, and MMP-
2, but only weakly expressed CK18 and vimentin. MMP-2 mRNA and protein levels were
significantly inhibited by RNA interference (P  < 0.05). Both MMP-2 siRNA and TIMP-2
overexpression inhibited MMP-2 activity and the in vitro invasiveness of ameloblastoma.
Conclusion:  These results indicate that inhibition of MMP-2 activity suppresses the local
invasiveness of ameloblastoma cells. This mechanism may serve as a novel therapeutic target in
ameloblastomas pursuant to additional research.
Background
Ameloblastomas are the most frequently encountered
tumors arising from odontogenic epithelium [1,2].
Although characterized as a benign neoplasm, ameloblas-
tomas are locally invasive and frequently recrudescent
tumors of the jaw [2]. Numerous studies have identified
both genetic and molecular alterations in these odon-
togenic tumors of the epithelium [3,4], but the mecha-
nisms underlying the local invasiveness of this neoplasm
have yet to be clarified.
Matrix metalloproteinases (MMPs) are a family of zinc-
and calcium-dependent proteolytic enzymes [4]. These
enzymes play central roles in the regulation of the extra-
cellular matrix during embryonic development and tissue
remodeling. MMPs also participate in tumor invasion and
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metastasis [5,6]. The major function of tissue inhibitors of
matrix metalloproteinases (TIMPs) is to inhibit the active
forms of MMPs in a 1:1 stoichiometric ratio via non-cov-
alent mechanisms [7,8]. Aberrant MMP activity in tumor
cells and the surrounding stromal tissues has been impli-
cated in tumor invasion and metastasis [9,10]. Previous
studies have shown that ameloblastomas have an elevated
expression of MMP-2, MMP-9, and vascular endothelial
growth factor (VEGF), and are void of or have an abnor-
mal expression of E-cadherin and TIMP-2 [11-14].
Therapeutic interventions that inhibit MMP activity
appear to be promising based on a number of in vitro and
in vivo tumor invasiveness studies [15-17]. To determine
whether inhibition of MMP-2 activity is capable of sup-
pressing the invasiveness of ameloblastomas, plasmids
were constructed and subsequently transfected into amel-
oblastoma cells to cause the overexpression of, or to
knockdown, MMP-2. This study was designed to test the
hypothesis that MMP-2 activity is involved in the invasive-
ness of ameloblastomas and that inhibition of MMP-2 is
a useful approach for treating ameloblastomas. The data
collected in this study indicate that siRNA targeting of
MMP-2 mRNA or TIMP-2 overxpression inhibits the activ-
ity of MMP-2 in ameloblastoma cells, which results in
reduced ameloblastoma cell invasiveness in vitro, indicat-
ing that inhibition of MMP-2 activity may serve as a novel
therapeutic target in the management of ameloblastomas.
Methods
Primary cell cultures and identification
The samples used in this study were obtained after obtain-
ing informed consent of each patient and with the
approval of the Sun Yet-sen University Ethics Committee.
Briefly, ameloblastoma tissues were minced and incu-
bated overnight in Dulbecco's modified Eagle medium
(DMEM, Invitrogen, CA, USA) containing 1 mg/mL colla-
genase I (Invitrogen) at 37°C. Collagenase-digested tis-
sues were plated onto 35 mm dishes coated with collagen
I (Invitrogen) in DMEM containing 10% fetal calf serum,
200 μg/ml streptomycin, and 200 IU/ml penicillin, and
incubated at 37°C with 5% CO2. When the cells were con-
fluent, they were divided again and used for the ensuing
experiments.
Immunocytochemistry was used to confirm the epithelial
origin of the ameloblastoma cells using the SP method as
described by the manufacturer (Maixin, Fuzhou, China).
The primary antibodies were anti-cytokeratin 14, 16, and
18 and anti-vimentin (Maixin). Immunofluorescence was
used to detect the expression of MMP-2, as described by
the product's manufacturer.
Plasmid construction and transient transfection
To generate the plasmid vector, pRNA-MMP-2, pRNA-
U6.1/neovector (Genscript, NJ, USA) containing a cGFP
sequence was used. MMP-2 shRNA contains a comple-
ment of a 21-nucleotide sequence (tgtgctgaaggacacactaaa,
GenBank NM-004530), which was separated by a 7-
nucleotide non-complementary spacer (CCACACC). A
control vector (pRNA-neg) was constructed in the same
way using a 21-nucleotide sequence (gattcaggtgtagaac-
gagca). These sequences were confirmed using nucleotide
BLAST to ensure that there was no homology with any
other known human gene. These annealed sequences
were inserted into the pRNA-U6.1/neo backbone after
digestion with BamH1 and HindIII. After amplification,
all vector constructs were verified by sequencing.
The pcDNA3 vector (Genscript) containing an enhanced
green fluorescence protein (EGFP) sequence was
employed to generate the plasmid vector, pcDNA-TIMP-2.
The cDNA encoding TIMP-2 was obtained via RT-PCR.
The primer sequence for TIMP-2 (723 bp, GenBank
NM003522) containing EcoRI and XhoI was as follows:
forward 5'cgatgaattcatgggcgccgcggcccgc3'; reverse
5'cgatctcgagttattatgggtcctcgatgagaaac3'. TIMP-2 cDNA was
subcloned into the clone site of the pcDNA3. Following
amplification, vector constructs were verified by sequenc-
ing.
The constructed plasmids were transiently transfected into
the cultured ameloblastoma cells using Lipofectamine
Plus reagent (Invitrogen), according to the manufacturer's
instructions. Transfected cells were subsequently used in
the following experiment.
Detection of MMP-2/TIMP-2 activity
MMP-2/TIMP-2 activity in the culture medium of the
ameloblastoma cells was detected by zymography accord-
ing to the method reported by Kleiner et al. [18]. Briefly,
10 μl of the medium from serum-free ameloblastoma cell
cultures was mixed with the same volume of sample
buffer and applied to a 10% (wt/vol) polyacrylamide gel
containing 1 mg/ml gelatin. Gels were incubated in 2.5%
Triton X-100 for 45 min after electrophoresis, then incu-
bated at 37°C overnight in a digestion buffer. Gels were
stained and destained. The bands were analyzed by an
auto-imaging analysis system (Kontron IBAS2.0, Ger-
many). All densitometry measurements were made
between samples in the same gel to ensure comparability.
For detection of TIMP-2 activity, all procedures were sim-
ilar to the detection of MMP-2 activity (described above),
except that the gel contained 1% (wt/vol) MMP-2 (Sigma,
St. Louis, MO, USA).BMC Cancer 2008, 8:182 http://www.biomedcentral.com/1471-2407/8/182
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RNA preparation and RT-PCR
Total RNA was extracted using an RNeasy mini kit (Qia-
gen), according to the manufacturer's instructions. RT-
PCR was performed using one-step RT-PCR assays (Qia-
gen). Specific primers for detecting mRNA transcripts of
the MMP-2 or TIMP-2 gene were as follows: MMP-2
(NM004530), 5'-AGCCACCCCTAAAGAGATCC-3' and
3'GTTCTAAGGCAGCCAGCAGT-5'; TIMP-2 (NM003
255), 5'-ATTTGACCCAGAGTGGAACG-3' and 3'-TCCT-
TCGGCGAGTTTATGGA-5'; and GAPDH (NM008084), 5'
GGTCGGAGTCAACGGATTTGGTCG-3' and 3'-CCTC-
CGACGCCTGCTTCACCAC-5'.
Transcript levels were normalized according to GAPDH
transcripts and the products were resolved by agarose elec-
trophoresis. The intensity was quantified by image-analy-
sis computer software (NIH Image).
Western blots
Western blotting was performed to detect MMP-2 and
TIMP-2 proteins (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Cells were harvested by trypsinization and
lysed with a radio-immune precipitation assay (RIPA)
lysis buffer (Santa Cruz Biotechnology). Total protein
concentrations were measured by the Bradford method
(Bio-Rad). Aliquots (30–50 μg) of cellular proteins were
resolved by SDS-PAGE (10%), then electrotransferred
onto PVDF membranes and immunoprobed. The protein-
antibody complexes were detected by chemiluminescence
(CSPD; Tropix, Bedford, MA, USA), according to the man-
ufacturer's protocol (Applied Biosystems, MA, USA). The
GAPDH gene was used as an internal control and the
band intensity was quantified.
In vitro cell invasion
The invasive ability of ameloblastoma cells was assayed in
transwell cell chambers (Costa, Cambrige, MA, USA),
according to the method reported by Kido et al. [19].
Briefly, polycarbonate filters with an 8.0 μm pore size
were precoated with fibronectin on the lower surface.
Matrigel was applied to the upper surface of the filters (5
μg/filter). Ameloblastoma cell suspensions (100 μl with 2
× 106 cells/ml) that had or had not been transfected were
added to the upper compartment and incubated for 72 h
at 37°C at 5% CO2. The filters were fixed with methanol
and stained with Giemsa stain. The cells invading the
lower surface through the Matrigel were manually
counted under a microscope. The rate of invasion was cal-
culated by the following equation: (number of cells
invading the lower surface in the control group – number
of cells invading the lower surface in the treated group)/
number of cells invading the lower surface in the control
group × 100%.
Statistical analysis
All experiments were performed in triplicate. Data are
expressed as the mean ± standard deviation (SD). Analysis
of variance (ANOVA) was used to compare differences
between treatment and control cells. A p < 0.05 was con-
sidered significant.
Results
Cells in primary culture
After ameloblastoma tissues were cultured for 18–36
hours, ameloblastoma cells either formed a colony or
migrated out from the ameloblastoma tissue and under-
went membraniform growth in which cells were arranged
like a slabstone (Figure 1A). Secondary cell cultures
showed large, flattened, or spindle-shaped morphology
(Figure 1B). Immunocytochemistry revealed that the cul-
tured ameloblastoma cells expressed normal levels of
cytokeratins 14 and 16 and only weakly expressed cytok-
eratin 18 and vimentin (Figure 1C), indicating that these
cultures were primarily comprised of ameloblastoma cells
of epithelial origin.
To investigate whether MMP-2 was expressed in the pri-
mary ameloblastoma cell cultures, immunofluorescence
was used. Ameloblastoma cells that were immunopositive
for MMP-2 showed green fluorescence in the cytoplasm
and red fluorescence in the cell nucleus under a fluores-
cent microscope (Figure 1D).
MMP-2 siRNA transfection decreased MMP-2 expression 
and activity
To investigate whether MMP-2 siRNA transfection
decreases MMP-2 expression and activity, ameloblastoma
cells were transfected with various doses of pRNA-MMP-2
(1–3 μg) and the protein level of MMP-2 was analyzed by
Western blots. MMP-2 siRNA transfection decreased
MMP-2 protein expression in both a dose- and time-
dependent manner compared with mock and scrambled
vector controls (Figure 2A). There were no differences
between the three control groups (p > 0.05), but a signifi-
cantly lower protein level of MMP-2 after transfection
with various doses of pRNA-MMP-2 (p < 0.05) were noted
compared with the three control groups. This MMP-2
inhibition was more pronounced in the cells transfected
with 2 or 3 μg of plasmid than in the 1 μg plasmid trans-
fection group (p < 0.05). No difference between the 2 and
3 μg plasmid transfection groups was noted (p > 0.05).
To determine whether the decreased production of MMP-
2 was due to a decrease in gene transcription, MMP-2 tran-
scripts were assessed via RT-PCR. As shown in Figure 2B,
the transcript levels of MMP-2 in MMP-2 transfected cells
were significantly lower than MMP-2 RNA levels in the
mock, lipidosome, and pRNA-negative transfected cells(p
< 0.05).BMC Cancer 2008, 8:182 http://www.biomedcentral.com/1471-2407/8/182
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Primary cultures of ameloblastoma cells Figure 1
Primary cultures of ameloblastoma cells. (A) Primary culture ameloblastoma cells formed a colony or migrated out from 
ameloblastoma tissue under phase-contrast microscopy (× 100). (B) Sub-cultured ameloblastoma cells had vigorous growth in 
2–4 passages. Cells were large and flattened or spindle-shaped under phase-contrast microscopy (× 200). (C) Immunocyto-
chemistry confirmed the epithelial origin of the ameloblastoma cells based on cytokeratin 14 and 16 expression; cytokeratin 18 
and vimentin were only weakly expressed (× 300). (D) Immunofluorescence for MMP-2 in ameloblastoma cells. Cells were 
examined and photographed under fluorescent microscopy. The green fluorescence shows the localization of MMP-2 and 
nuclei were counterstained with propidium iodine (PI) which fluoresced red (× 300).BMC Cancer 2008, 8:182 http://www.biomedcentral.com/1471-2407/8/182
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Effect of MMP-2 siRNA on ameloblastoma cells Figure 2
Effect of MMP-2 siRNA on ameloblastoma cells. Ameloblastoma cells were transfected with mock, lipofectamine, 
pRNA-neg, pRNA-MMP-2 (1 μg), pRNA-MMP-2 (2 μg), and pRNA-MMP-2 (3 μg) for the indicated times. GAPDH was used as 
an internal control to normalize the amounts of protein or mRNA. The relative protein or mRNA level of MMP-2 was 
depicted as the ratio of the density of MMP-2 to GAPDH for the same time point. The results shown are representative of 
triplicate experiments. *Compared with the mock, lipifectamine or vector controls, respectively, p < 0.05; #Compared with 
the 1 μg plasmid transfection group, p < 0.05. (A) Western blots were used to analyze MMP-2 protein levels in MMP-2 siRNA-
transfected ameloblastoma cells. MMP-2 siRNA transfection decreased MMP-2 protein expression levels in a dose- and time-
dependent manner compared with mock and scrambled vector controls. (B) RT-PCR was employed to detect the transcrip-
tion of MMP-2 after MMP-2 siRNA transfection. Transcript levels of MMP-2 in MMP-2 siRNA-transfected cells were signifi-
cantly reduced in a dose- and time-dependent manner compared with cells transfected with mock and lipofectamine and 
pRNA-neg. (C) Zymographic analysis for MMP-2 activity in the conditioned medium of ameloblastoma cells transfected with 
pRNA-MMP-2 for 96 h. Both latent and active form of MMP-2 and MMP-9 were detected in the gelatin zymogram. MMP-2 
siRNA transfection inhibited MMP-2 activity in a dose-dependent manner in ameloblastoma cells.BMC Cancer 2008, 8:182 http://www.biomedcentral.com/1471-2407/8/182
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Overexpression of TIMP-2 inhibited the MMP-2 activity of ameloblastoma cells Figure 3
Overexpression of TIMP-2 inhibited the MMP-2 activity of ameloblastoma cells. Ameloblastoma cells were trans-
fected with mock, lipofectamine, pcDNA-neg, pcDNA-TIMP-2 (1 μg), pcDNA-TIMP-2 (2 μg), or pcDNA-TIMP-2 (3 μg) for 72 
h. GAPDH was included as an internal control to normalize the amounts of protein or mRNA. The relative protein or mRNA 
level of TIMP-2 was depicted as the ratio of the density of TIMP-2 to GAPDH for the same time point. The results are a repre-
sentative experiment among three. *Compared with the mock, lipifectamine or vector controls, respectively, p < 0.05. (A) 
Western blotting (WB) was used to detect TIMP-2. TIMP-2 protein levels increased in ameloblastoma cells after transfection 
with pcDNA-TIMP-2. (B) RT-PCR was used to detect the transcription of TIMP-2 after pcDNA-TIMP-2 transfection. Tran-
script levels of TIMP-2 in TIMP-2-transfected cells were significantly higher compared with cells transfected with mock and 
lipofectamine and pcDNA-neg. (C) Zymographic analysis for MMP-2 and TIMP-2 activity in the conditioned medium of amelob-
lastoma cells transfected with various doses of pcDNA-TIMP-2. The zymography assay revealed that pcDNA-TIMP-2 transfec-
tion decreased MMP-2 activity. The inhibition rates were 31.88, 67.87, and 43.57% for 1, 2, and 3 μg, respectively. Reverse 
gelatin zymography showed that pcDNA-TIMP-2 transfection increased TIMP-2 activity.BMC Cancer 2008, 8:182 http://www.biomedcentral.com/1471-2407/8/182
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To investigate whether MMP-2 activity was associated
with MMP-2 knockdown, a zymogram assay was used to
detect enzyme activity in the culture medium following
transfection with various doses of pRNA-MMP-2 for 96 h
(Figure 2C). Both latent and active forms of MMP-2 and
MMP-9 were detected in the gelatin zymogram. The MMP-
9 was not different after MMP-2 knockdown compared to
pre-knockdown values. MMP-2 siRNA transfection inhib-
ited MMP-2 activity in a dose-dependent manner whereas
no difference in MMP-2 activity was identified in the three
control groups (p > 0.05). After transfection of ameloblas-
toma cells with various doses of pRNA-MMP-2, the activ-
ity of MMP-2 was significantly decreased compared with
the three control groups (p < 0.05).
Overexpression of TIMP-2 inhibited MMP-2 activity
To determine the effect of TIMP-2 overexpression on
MMP-2 activity, ameloblastoma cells were transfected
with various doses of pcDNA-TIMP-2 (1–3 μg). Western
blots and RT-PCR showed that the levels of both TIMP-2
mRNA and TIMP-2 protein in the TIMP-2 transfected cells
were significantly higher than that of cells transfected with
mock, lipofectamine, and pcDNA-neg (p < 0.05; Figures
3A and 3B). Further, zymography and reverse gelatin
zymography assays revealed that pcDNA-TIMP-2 transfec-
tion decreased MMP-2 activity and increased TIMP-2
activity in ameloblastoma cells (Figure 3C). While no dif-
ference between the three control groups were noted (p >
0.05), significantly lower MMP-2 activity and significantly
higher TIMP-2 activity were noted following transfection
with various doses of pcDNA-TIMP-2 (p < 0.05).
Effect of MMP-2 siRNA or TIMP-2 overexpression on the 
invasiveness of ameloblastoma cells
The effect of MMP-2 knockdown and TIMP-2 overexpres-
sion on ameloblastoma invasion was assessed using
Matrigel-coated transwells and the results are summarized
in Table 1. MMP-2 siRNA and pcDNA-TIMP-2 each inhib-
ited the invasion of ameloblastoma cells through the
Matrigel compared to the mock, lipifectamine, and vector-
transfected control cells. While there was no difference
between the invasion of cells in the three control groups
(p > 0.05), significantly fewer cells invaded through the
Matrigel after transfection with various doses of pcDNA-
TIMP-2 or pRNA-MMP-2 (p < 0.05) compared with the
three control groups. Further, a significant difference in
inhibition of invasion was noted between the cells trans-
fected with 1, 2, or 3 μg of pRNA-MMP-2 or pcDNA-TIMP-
2, but no significant differences existed between cells
transfected with 2 or 3 μg of pRNA-MMP-2 or pcDNA-
TIMP-2. Specifically, the invasiveness of ameloblastoma
cells after transfection with 1, 2 or 3 μg of pRNA-MMP-2
was decreased by 15.3, 55.5, and 61.3%, respectively, and
24.2, 53.3, and 50.5% in cells transfected with pcDNA-
TIMP-2, respectively.
Discussion
The goal of this study was to determine whether inhibi-
tion of MMP-2 activity was capable of suppressing the
local invasiveness of human ameloblastoma cells. This
was accomplished using an MMP-2 gene knockdown
approach or TIMP-2 overexpression and subsequently
detecting the relationship between MMP-2 activity and
the local invasiveness of ameloblastoma cells.
To date, three approaches for targeting MMP-2 activity
have been utilized: 1) the in vitro and in vivo delivery of
naturally occurring inhibitors of MMP-2 (i.e., TIMP); 2)
the design and delivery of novel inhibitory molecules or
modifications of naturally occurring inhibitors; and 3)
targeting MMP-2 mRNA via various gene silencing strate-
gies [20]. Previous studies performed by our group
revealed that the MMP-2 inhibitor, Ro31-9790, inhibited
adhesion and invasion of ameloblastoma cells in primary
Table 1: Analysis of the effect of MMP-2 siRNA or TIMP-2 overexpression on ameloblastoma cell invasion.
Group Invaded cells (Cells/Well) Inhibition rate of invasion
MMP-2siRNA
Mock 137 ± 21 0
Lipofectamine 129 ± 18 5.8
pRNA-neg 131 ± 28 4.4
pRNA-MMP-2(1 μg) 116 ± 24* 15.3
pRNA-MMP-2(2 μg) 61 ± 16* 55.5
pRNA-MMP-2(3 μg) 53 ± 20* 61.3
TIMP-2 overexpression
Mock 128 ± 18 0
Lipofectamine 123 ± 21 3.9
pcDNA-neg 117 ± 16 8.6
pcDNA-TIMP-2(1 μg) 97 ± 25* 24.2
pcDNA-TIMP-2(2 μg) 59.8 ± 23* 53.3
pcDNA-TIMP-2(3 μg) 63.4 ± 19* 50.5
*Compared with the mock, lipifectamine or vector controls, respectively, P < 0.05.BMC Cancer 2008, 8:182 http://www.biomedcentral.com/1471-2407/8/182
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cell cultures [21]. While Ro31-9790 did not alter the
expression of either MMP-2 or TIMP-2, Ro31-9790 did
inhibit the activity of MMP-2. This led to the supposition
that the suppression of the local invasiveness of amelob-
lastoma cells may be related to inhibition of MMP-2 activ-
ity.
Utilization of siRNAs is one of the most effective gene
silencing methods and is a promising new approach in the
analysis of gene function and gene therapy [22-25].
Numerous studies have used siRNAs to analyze the func-
tion of MMP-2 [26-28], but to date no studies have uti-
lized this technique with ameloblastomas. Therefore, we
investigated whether siRNAs targeted at MMP-2 are capa-
ble of inhibiting the activity of MMP-2 in ameloblastoma
cells. siRNAs against MMP-2 significantly inhibited MMP-
2 mRNA expression and MMP-2 protein levels in primary
ameloblastoma cell cultures. Furthermore, MMP-2siRNA
transfection decreased the activity of MMP-2.
The conversion of MMP proenzymes to the activated
forms is controlled by the stoichiometric binding of
TIMPs which are synthesized by cells, such as fibroblasts,
endothelial cells, and tumor cells [29]. The ability of
TIMPs to inhibit the activity of MMPs is known to signifi-
cantly suppress tumor invasion and metastasis [5,30,31].
To determine whether TIMP-2 inhibited the activity of
MMP-2 in ameloblastoma cells, plasmids were con-
structed to overexpress TIMP-2. TIMP-2 overexpression
inhibited MMP-2 activity in ameloblastoma cells. This
outcome suggested that TIMP-2 might suppress invasive-
ness in ameloblastomas in humans.
The underlying molecular mechanisms resulting in local
invasion by ameloblastomas are closely related to the pro-
teolytic degradation of the basement membrane. Among
the proteases thought to be involved in ameloblastoma
invasion, attention has focused on MMP-2 [11,12,14,21].
To investigate whether inhibition of MMP-2 activity will
suppress the invasiveness of ameloblastoma cells, we
knocked down MMP-2 by RNA interference or overex-
pressed TIMP-2. Both MMP-2 knockdown and TIMP-2
overexpression inhibited the activity of MMP-2. The inva-
sion assay showed that the ability of ameloblastoma cells
to invade the lower surface of the filter through the
Matrigel was significantly inhibited in both MMP-2
knockdown or TIMP-2 overexpression cells compared to
the control cultures.
Conclusion
In summary, these data indicate that siRNA targeting of
MMP-2 mRNA or TIMP-2 overxpression using a plasmid-
based system effectively inhibited the activity of MMP-2 in
ameloblastoma cells, which subsequently resulted in
reduced ameloblastoma cell invasiveness in vitro. This
study provided evidence that inhibition of MMP-2 activity
may serve as a novel therapeutic target in the clinical man-
agement of ameloblastoma. Further research is warranted.
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